Title
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage) for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Phase
Phase 2Lead Sponsor
Agenus Inc.Study Type
InterventionalStatus
Terminated Results PostedIndication/Condition
Renal Cell CarcinomaIntervention/Treatment
vitespen ...Study Participants
12The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked immunosorbent spot (ELISPOT) assay.
The study consists of two parts: Part 1 with Part 1a (Assessment of Immune Variation) and Part 1b (Assay Standardization), and Part 2 (Immune Monitoring Study). The study was terminated early with 12 participants enrolled only in Part 1a and Part 1b. Part 2 of the study involved randomization after 8 doses of HSSPC-96. After the 8 doses of HSSPC-96 administered in Part 2, the participants were to be randomized to the treatment extension arm or the placebo extension arm. There were no participants enrolled in Part 2 since the study was terminated early. Therefore, no randomization occurred in the conduct of this study and only a single arm was enrolled.
Participants will receive up to 8 administrations of HSPPC-96 25 µg intradermally over 3 months (4 weekly doses, followed by 4 bi-weekly doses [at Weeks 14, 15, 16, 17 19, 21, 23, and 25 in Part 1a and at Weeks 1-4, 6, 8, 10, 12 in Part 1b). Participants will remain untreated with HSPPC-96 for the initial 3-month period in Part 1a for immune monitoring blood draw.
Inclusion Criteria: Confirmation of histological diagnosis of renal cell carcinoma (RCC) with evidence of >= 25% clear cell carcinoma American joint committee on cancer tumor/node/metastasis tumor stage at intermediate risk for recurrence At least 8 doses of vaccine available from participant's tumor Life expectancy of at least 3 months Eastern cooperative oncology group performance status of 0 or 1 Cardiovascular disease status of new york heart association class less than 2 Adequate hematopoietic, renal and hepatic function Negative serology tests for human immunodeficiency virus (HIV), human T-cell lymphotrophic virus (HTLV-1), hepatitis B surface antigen (HBsAg), anti- hepatitis C virus antibodies (anti-HCV-Ab) Females must have negative pregnancy test Exclusion Criteria: Evidence of metastatic or residual RCC Documented radiological enlarged lymph nodes Females who are pregnant or breastfeeding Use of any other investigational product from 4 weeks post-surgery Splenectomy performed during nephrectomy
| Event Type | Organ System | Event Term | HSPPC-96 Vaccine |
|---|
The ELISPOT assay was not developed for this study and no immunogenicity data are available.
